Affordable Riociguat for Pulmonary Hypertension - How To Get It Worldwide

Summary - Riociguat (Adempas®) is the first and only medicine approved for chronic thromboembolic pulmonary hypertension in patients who can't get surgery or whose disease persists after surgery. But the branded version costs over $14.5K per month in the United States. MedsPartner provides generic Riociguat at $145 for the same quantity. That's 99% savings for patients worldwide who need this life-saving treatment. This blog describes the personal import process to access the affordable generic.

Riociguat is an oral medication used to treat serious forms of pulmonary hypertension, including pulmonary arterial hypertension (PAH) and chronic thromboembolic pulmonary hypertension (CTEPH). It works by stimulating an enzyme called soluble guanylate cyclase (sGC), which helps relax blood vessels in the lungs and improves blood flow - reducing strain on the heart. 

Riociguat is sold under the brand name Adempas®. While clinically effective, the branded version is notably expensive - costing thousands of dollars in the US. MedsPartner offers generic Riociguat manufactured in FDA/EMA-approved facilities to patients across the globe, including USA, UK, New Zealand, Australia and many other countries. Here is an overview of the medicine and the personal import process.

How does Riociguat help Pulmonary Hypertension Patients - Mechanism of Action?

Chronic thromboembolic pulmonary hypertension happens when blood clots get stuck in your lung arteries and don't dissolve. Unlike acute pulmonary embolism where clots form suddenly, CTEPH involves organized scar tissue that builds up over months to years. These chronic blockages force your heart to pump harder, eventually leading to right heart failure.

Surgery - pulmonary endarterectomy - is the only cure. Skilled surgeons can physically remove the organized clots and scar tissue. But up to 40% of CTEPH patients are technically inoperable due to clot location in small distal vessels, medical issues, or severe lung disease. Another subset undergoes surgery successfully, but pressure stays elevated or returns.

For decades, these patients had no approved medical therapy. Drugs approved for pulmonary arterial hypertension don't work well in CTEPH because the underlying problem isn't small vessel disease - it's physical obstruction.

Riociguat changed that in 2013 as the world's first and still only medication approved specifically for inoperable or persistent/recurrent CTEPH. It helps open up blood vessels in the lungs by boosting a natural pathway that relaxes them, making it easier for blood to flow. In the pivotal PATENT-1 study, Riociguat significantly improved patients’ overall heart–lung function compared to placebo 

Riociguat vs. Sildenafil for treating pulmonary hypertension?

Riociguat and Sildenafil both help relax blood vessels in the lungs, but they work differently.

Sildenafil (a PDE-5 inhibitor) works by blocking an enzyme that breaks down cyclic GMP. This allows more cyclic GMP to build up - which relaxes blood vessels. It's approved for PAH but not CTEPH.

Riociguat is a soluble guanylate cyclase stimulator - a completely different class. It has dual action: it directly creates cyclic GMP even when nitric oxide levels are low, and it makes the system more sensitive to whatever nitric oxide is present.

This matters in CTEPH because the physical clots impair normal nitric oxide signaling. Riociguat's ability to work independently of nitric oxide gives it an advantage.

Both are promising options for pulmonary hypertension, but Riociguat is the only one specifically approved for CTEPH - which your doctor can help you with.

Are there any recent updates on Riociguat availability and CTEPH treatment?

Generic riociguat not yet available in US

While generic versions of riociguat exist in some markets, they are not currently available through US pharmacies, where branded Adempas® remains the dominant option.

Balloon pulmonary angioplasty emerges as alternative

For some inoperable patients, balloon pulmonary angioplasty - threading catheters into lung arteries to expand narrowed segments - offers a less invasive option than surgery. This technique is growing but requires specialized centers and doesn't replace medical therapy for many patients.

Riociguat price - why does branded Adempas® cost so much?

Riociguat was developed as the first soluble guanylate cyclase stimulator to address unmet needs in CTEPH patients. Research and clinical trial expense in this rare disease justified the high pricing at launch.

It received orphan drug status, and a generic version is still not widely available in the United States, which keeps prices high.

Access varies worldwide - many patients face high out-of-pocket costs or simply can’t get the medicine in their country.

MedsPartner sources Riociguat from FDA- and EMA-approved manufacturers in India. The generic offers comparable benefits at a small fraction of the price.

How much can I save on medicine bills with generic Riociguat from MedsPartner?

Pricing comparison - 90 tablets 1.5mg

Standard dosing starts at 1mg three times daily, titrating up based on blood pressure tolerance to a maximum of 2.5mg three times daily. Most patients end on 1.5-2.5mg three times daily, requiring 90 tablets monthly.

Branded Adempas® costs $14,542 for 90 tablets or roughly $174,500 annually. MedsPartner's generic costs $131 for 90 tablets or $1,570 per year. This means 99% savings amounting to $172,930 every year.

Is personal importation of pulmonary hypertension drugs like Riociguat legal?

Many countries allow personal medication imports in limited quantities for serious diseases like CTEPH. Requirements typically include valid prescriptions from your pulmonary hypertension specialist, documentation of personal use, and quantities matching 1-3 months of treatment.

MedsPartner helps patients and families understand their country's rules for personal imports and prepares their orders accordingly. We have handled thousands of international shipments over 9 years to patients in more than 45 countries, managing documentation for each destination. We offer support across USA, UK, New Zealand, Australia and various parts of South America, Africa, Eurasia and the Middle East.

How a CTEPH patient in São Paulo accessed Riociguat after inoperable diagnosis

Marcos got diagnosed with CTEPH at 46 after months of progressive shortness of breath. Right heart catheterization showed mean pulmonary artery pressure of 48 mmHg - severely elevated. His pulmonary hypertension team reviewed his CT angiogram and decided the clots sat too distally for safe surgical removal. He was inoperable.

His pulmonologist recommended Riociguat, explaining it was the only medication specifically approved for his condition. Brazil's public healthcare system (SUS) doesn't routinely cover Riociguat. Private insurance might pay partial costs after authorization, but he was looking at R$12,000-15,000 monthly out-of-pocket - impossible on his salary.

A CTEPH support group member mentioned importing generic versions. Marcos contacted us and learned Brazil permits personal medication importation with proper documentation from his physician.

We sourced from an FDA/EMA-approved manufacturer and delivered to São Paulo in 12 days. Cost was R$800 (about USD $145) for 100 tablets - enough for a full month plus extras.

"Being told there's only one drug that might help, but you can't afford it - that was devastating," Marcos said. "Finding an affordable source meant I could actually treat my disease."

Your questions about Riociguat price and access answered

Q1. What if insurance denies Riociguat coverage?

A - Denials sadly happen frequently for orphan drugs treating rare diseases. Appeal immediately with documentation from your PH specialist showing inoperable CTEPH or persistent/recurrent PH post-surgery. Bayer operates the Aim Patient Support Program offering copay assistance for commercially insured US patients. When these don't work, MedsPartner provides access to quality-assured generic Riociguat at 99% savings versus US branded costs.

Q2. How can I trust MedsPartner's generic Riociguat is equivalent to branded Adempas?

A - We source Riociguat only from manufacturers with FDA/EMA certifications. The generics must prove bioequivalence for approval - which means they have the same active ingredients and similar action as branded Adempas. We provide manufacturer data and expiry dates with every order for full transparency and quality control. Our 9-year track record includes 30,000+ successful deliveries across more than 45+ countries, supported by a 4.5-star Trustpilot rating.

Q3. How does ordering Riociguat from MedsPartner work?

A - Visit MedsPartner's Riociguat page and upload your prescription without making any payment. Our team verifies it and checks your country's importation rules. If personal import is allowed in your country, we explain the rules and provide final pricing covering medication and shipping. After payment, we ship your order as per your country's requirements through international couriers.

Q4. I'm a pulmonary hypertension specialist - how can I help my patient access generic Riociguat?

A - Email support@medspartner.com with patient details and prescription. We work directly with them on logistics and ship the medicines to their doorstep as per your country's personal import laws.

Q5. What are the side effects of Riociguat?

A - Headache, dizziness, and stomach issues are the most common side effects of Riociguat and its brand name version. Low blood pressure can happen - Riociguat lowers blood pressure as it dilates blood vessels, so careful monitoring is important. Rarely, bleeding can occur, especially in patients on blood thinners for CTEPH. Riociguat can cause serious birth defects - women who could become pregnant must use two forms of birth control and have regular pregnancy tests.

Q6. How much will I save with MedsPartner's generic Riociguat?

A - At standard dosing of 1.5-2.5mg three times daily (90 tablets monthly), branded Adempas® costs about $14,500 per month in the United States. MedsPartner's generic costs $131 per month. That's monthly savings of $14,369 - a 99% cost reduction. Over a year, you save roughly $172,400 compared to branded pricing.

Get affordable options for inoperable pulmonary hypertension

When surgery can't remove the clots from your lungs, or when pulmonary hypertension persists despite successful surgery, Riociguat offers the only approved pharmacotherapy specifically tested for your condition.

Access to Riociguat shouldn't depend on insurance companies deciding coverage for orphan drugs, or on paying $174,000 annually for a medication you'll need indefinitely. When you have chronic blood clots damaging your lung circulation and no surgical option, medical therapy isn't optional - it's essential for survival.

MedsPartner provides legitimate access to quality-assured generic Riociguat for patients worldwide who can't get it locally or afford standard pricing.

If you are facing cost or availability issues with Riociguat (Adempas®), contact us at support@medspartner.com for assistance or place your order for the generic on our website.

About the Author - Gunjan Agrawal brings deep experience in global healthcare logistics and cross-border medicine access. At MedsPartner - she oversees the intricate process of delivering essential treatments to patients worldwide - ensuring safety, affordability, and regulatory compliance at every step. Her work draws on years of hands-on expertise in supplier management, quality assurance & international coordination - experience that has shaped her nuanced understanding of the real-world challenges in making healthcare truly accessible.